- 暂无数据
简体中文
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
On February 7th, at the Wuhan Semiconductor Laser Equipment Industry Innovation Joint Laboratory located in the HGTECH Technology Intelligent Manufacturing Future Industrial Park, Huang Wei, the technical director of the laboratory and the director of HGTECH Technology's semiconductor product line, gestured with his hands to introduce the principle of "glass through-hole technology" to Changjiang ...
Laser Cladding, also known as laser cladding or laser cladding, is a method of adding cladding material to the surface of the substrate and using a high-energy density laser beam to melt it together with the thin layer on the surface of the substrate. It forms a metallurgical bonded additive cladding layer on the surface of the substrate, which can be used for surface strengthening and defect repa...
Lithography is one of the core processes in semiconductor manufacturing, and extreme ultraviolet lithography technology, as a new generation lithography technology, is also in a rapid development stage. The basic principle is to use photoresist (also known as photoresist) to form corrosion resistance due to photochemical reactions after being photosensitive, and to engrave the patterns on the mask...
Researchers from Bayreuth University and Konstanz University are developing new methods to control ultra short laser emission using soliton physics and two pulse combs in a single laser. This method has the potential to greatly accelerate and simplify laser applications.Traditionally, the pulse interval of lasers is set by dividing each pulse into two pulses and delaying them at different, mechani...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...